Hearing Loss Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Hearing Loss pipeline constitutes 32+ key companies continuously working towards developing 35+ Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Hearing Loss Overview

Hearing loss is the partial or complete loss of hearing in one or both ears, ranging from mild to profound. There are many causes, and it can affect anyone at any age, but it’s most common in people older than 60. Hearing loss in older adults is known medically as presbycusis.


Hearing Loss Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hearing Loss Market.


The Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Some of the key takeaways from the Hearing Loss Pipeline Report:

Companies across the globe are diligently working toward developing novel Hearing Loss treatment therapies with a considerable amount of success over the years. Hearing Loss Key players such as – Acousia Therapeutics, Frequency Therapeutics, Acousia Therapeutics, Decibel Therapeutics, Otonomy, Inc., Pipeline Therapeutics, AudioCure Pharma GmbH, Frequency Therapeutics, Sensorion, and others, are developing therapies for the Hearing Loss treatment 
Hearing Loss Emerging therapies such as – ACOU 082, FX-345, ACOU085, DB-020, OTO 413, PIPE 505, AC102, FX-322, SENS-401, and others are expected to have a significant impact on the Hearing Loss market in the coming years.   
In January 2023, Sensorion announces that the first patient has been enrolled in its Phase 2a Proof of Concept clinical trial ofSENS-401 (Arazasetron) in patients suffering from Cisplatin-Induced Ototoxicity. The exploratory Phase 2a, multicenter, randomized, controlled, open-label study, NOTOXIS, aims at evaluating the efficacy of SENS-401 to prevent ototoxicity induced bycisplat in in adult patients with a neoplastic disease
In August 2022, Sensorion initiated a Phase II a, open-label, randomized and controlled study investigating repeated twice-daily administration of oral SENS-401 in adult participants with moderately severe to profound hearing loss who have already agreed to undergo cochlear implant surgery justified by their hearing impairment


Route of Administration

Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 



Molecule Type

Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Small molecule
Gene therapy 


Hearing Loss Pipeline Therapeutics Assessment

Hearing Loss Assessment by Product Type
Hearing Loss By Stage and Product Type
Hearing Loss Assessment by Route of Administration
Hearing Loss By Stage and Route of Administration
Hearing Loss Assessment by Molecule Type
Hearing Loss by Stage and Molecule Type


DelveInsight’s Hearing Loss Report covers around 35+ products under different phases of clinical development like-

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration


Some of the key companies in the Hearing Loss Therapeutics Market include:

Key companies developing therapies for Hearing Loss are – Decibel Therapeutics, Frequency Therapeutics, Otonomy Inc., Cochlear Ltd., MED-EL, Advanced Bionics AG, GN Hearing, Sonova Holding AG, Oticon Medical, Sivantos Group, and others.


Emerging Hearing Loss Drugs Under Different Phases of Clinical Development Include:

ACOU 082: Acousia Therapeutics
FX-345: Frequency Therapeutics
ACOU085: Acousia Therapeutics
DB-020: Decibel Therapeutics
OTO 413: Otonomy, Inc.
PIPE 505: Pipeline Therapeutics
AC102: AudioCure Pharma GmbH
FX-322: Frequency Therapeutics
SENS-401: Sensorion


Get a Free Sample PDF Report to know more about Hearing Loss Pipeline Therapeutic Assessment- 



Hearing Loss Pipeline Analysis:

The Hearing Loss pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Hearing Loss with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hearing Loss Treatment.
Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hearing Loss market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Further Hearing Loss product details are provided in the report. Download the Hearing Loss pipeline report to learn more about the emerging Hearing Loss therapies


Hearing Loss Pipeline Market Drivers

Rapidly growing incidence of acute sensorineural hearing loss
Rise in geriatric population


Hearing Loss Pipeline Market Barriers

Challenges associated with the delivery of therapeutics for Sensorineural Hearing Loss
Poor understanding of the specific underlying pathologies


Scope of Hearing Loss Pipeline Drug Insight    

Coverage: Global
Key Hearing Loss Companies: Acousia Therapeutics, Frequency Therapeutics, Acousia Therapeutics, Decibel Therapeutics, Otonomy, Inc., Pipeline Therapeutics, AudioCure Pharma GmbH, Frequency Therapeutics, Sensorion, and others
Key Hearing Loss Therapies: ACOU 082, FX-345, ACOU085, DB-020, OTO 413, PIPE 505, AC102, FX-322, SENS-401, and others
Hearing Loss Therapeutic Assessment: Hearing Loss current marketed and Hearing Loss emerging therapies
Hearing Loss Market Dynamics: Hearing Loss market drivers and Hearing Loss market barriers 


Request for Sample PDF Report for Hearing Loss Pipeline Assessment and clinical trials


Table of Contents


Hearing Loss Report Introduction


Hearing Loss Executive Summary


Hearing Loss Overview


Hearing Loss- Analytical Perspective In-depth Commercial Assessment


Hearing Loss Pipeline Therapeutics


Hearing Loss Late Stage Products (Phase II/III)


Hearing Loss Mid Stage Products (Phase II)


Hearing Loss Early Stage Products (Phase I)


Hearing Loss Preclinical Stage Products


Hearing Loss Therapeutics Assessment


Hearing Loss Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Hearing Loss Key Companies


Hearing Loss Key Products


Hearing Loss Unmet Needs


Hearing Loss Market Drivers and Barriers


Hearing Loss Future Perspectives and Conclusion


Hearing Loss Analyst Views




About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.


Download Sample PDF Report to know more about Hearing Loss drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: